X0508 4 2025-03-05 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001726096 Daniell Richard C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL false true false false Exec. VP, European Commercial true Ordinary Shares 2025-03-05 4 M false 22576 A 119345 D Ordinary Shares 2025-03-05 4 S false 22576 15.9139 D 96769 D Ordinary Shares 2025-03-05 4 S false 48385 15.901 D 48384 D Restricted Share Units 2025-03-05 4 M false 22576 0 D Ordinary Shares 22576 0 D Restricted Share Units 2025-03-05 4 A false 69182 0 A Ordinary Shares 69182 69182 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.795 to $16.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.9 to $15.905, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 2025-03-07